2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Factor Xa

Factor Xa

Fxa

Factor Xa

Related Products

PDF 0.5 MB

Factor Xa, a trypsin-like serine protease, is situated at the critical juncture between the intrinsic and extrinsic pathways, catalyzing the conversion of prothrombin to thrombin, and hence plays a pivotal role in the final common pathway of the cascade and has become an important target in the discovery and development of new anticoagulants. Factor Xa is a key protease of the coagulation pathway whose activity is known to be in part modulated by binding to factor Va and sodium ions.

Blood coagulation involves a complex cascade of enzymatic reactions, ultimately generating fibrin, the basis of all blood clots. This cascade is comprised of two arms, the intrinsic and extrinsic pathways which converge at factor Xa to form the common pathway. Factor Xa activates prothrombin to thrombin, which in turn catalyzes the conversion of fibrinogen to fibrin.

Factor Xa Related Products (69):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-B1560
    Bismuth subgallate
    		≥98.0%
    Bismuth subgallate, a hemostatic agent, acts on coagulation factor XII (Hageman factor), leading to the activation of the coagulation cascade and improving early formation of a fibrin clot.
    Bismuth subgallate
  • HY-117290
    BMS-962212
    		Inhibitor 99.76%
    BMS-962212 is a direct, reversible, selective factor XIa (FXIa) inhibitor . BMS-962212 is well tolerated, with fast onset of pharmacodynamic (PD) responses and rapid elimination. BMS-962212 increases exposure dependently in activated partial thromboplastin time, and decreases exposure dependently in FXI clotting activity.
    BMS-962212
  • HY-14853
    Darexaban
    		Inhibitor 99.60%
    Darexaban (YM150) is a potent, selective and orally active factor Xa (FXa) inhibitor with an IC50 of 54.6 nM. Darexaban shows high selectivity against other related serine proteases, such as trypsin, thrombin, and kallikrein. Darexaban has anticoagulant and antithrombotic effects.
    Darexaban
  • HY-76948
    5-R-Rivaroxaban
    		Inhibitor 99.97%
    5-R-Rivaroxaban is (R)-enantiomer of Rivaroxaban. Rivaroxaban (BAY 59-7939) is a highly potent and selective, direct Factor Xa (FXa) inhibitor, achieving a strong gain in anti-FXa potency (IC50 0.7 nM; Ki 0.4 nM).
    5-R-Rivaroxaban
  • HY-P99794
    Osocimab
    		Inhibitor
    Osocimab (BAY 1213790), an anti-FXIa antibody (Ki=2.4 nM; EC50=0.2 nM). FXI inhibition may reduce the risk of thrombosis. Osocimab inhibits thrombin generation, and prolongs activated partial thromboplastin time. Osocimab exhibits anticoagulant effects.
    Osocimab
  • HY-P4245
    D-Pro-Phe-Arg-Chloromethylketone
    		Inhibitor 98.95%
    D-Pro-Phe-Arg-Chloromethylketone, a inhibitor of coagulation factor XII and plasma kallikrein, plays an important role in thrombosis and inflammation.
    D-Pro-Phe-Arg-Chloromethylketone
  • HY-76971
    Dechloro Rivaroxaban
    		Inhibitor 99.94%
    Dechloro Rivaroxaban is a highly selective, orally active inhibitor of Factor Xa. Dechloro Rivaroxaban inhibits human free FXa with a Ki of 0.4 nM. Dechloro Rivaroxaban inhibits prothrombinase activity and fibrin-associated FXa activity with IC50s of 2.1 nM and 92 nM, respectively.
    Dechloro Rivaroxaban
  • HY-10264A
    Edoxaban tosylate
    		Inhibitor 99.84%
    Edoxaban (DU-176b) tosylate is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with Kis of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban tosylate exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban tosylate can be used for preventing thromboembolic disease research.
    Edoxaban tosylate
  • HY-50667S
    Apixaban-13C,d3
    		Inhibitor 99.89%
    Apixaban-13C,d3 is a deuterium and 13C labeled Apixaban. Apixaban is a highly selective, reversible inhibitor of Factor Xa with Ki of 0.08 nM and 0.17 nM in human and rabbit, respectively[1].
    Apixaban-<sup>13</sup>C,d<sub>3</sub>
  • HY-134686
    Edoxaban impurity 4
    		Inhibitor 99.08%
    Edoxaban impurity 4 is an impurity of Edoxaban. Edoxaban (DU-176) is a selective, potent and orally active factor Xa (FXa) inhibitor with Kis of 0.561 nM and 2.98 nM for free FXa and prothrombinase, respectively. Edoxaban is an anticoagulant agent and can be used for stroke prevention.
    Edoxaban impurity 4
  • HY-153480
    ARC19499
    		Inhibitor
    ARC19499 is an aptamer that inhibits tissue factor pathway inhibitor (TFPI) , thereby enabling clot initiation and propagation via the extrinsic pathway. The core aptamer binds tightly and specifically to TFPI. ARC19499 blocks TFPI inhibition of both factor Xa and the TF/factor VIIa complex. ARC19499 corrects thrombin generation in hemophilia A and B plasma and restores clotting in FVIII-neutralized whole blood.
    ARC19499
  • HY-10268S
    Betrixaban-d6
    		Inhibitor 98.81%
    Betrixaban-d6 is a deuterium labeled Betrixaban. Betrixaban is a highly potent, selective, and orally efficacious factor Xa (fXa) inhibitor[1].
    Betrixaban-d<sub>6</sub>
  • HY-150224
    GalNAc unconjugated/naked Fitusiran sodium
    		Inhibitor
    GalNAc unconjugated/naked Fitusiran (sodium), an small interfering RNA without GalNAc conjugation, specifically targets antithrombin (AT) messenger RNA to lower production of AT in the liver. Fitusiran increases thrombin generation and has the potential for the research of the hemophilia.
    GalNAc unconjugated/naked Fitusiran sodium
  • HY-10264S
    Edoxaban-d6
    		Inhibitor ≥99.0%
    Edoxaban-d6 is deuterium labeled Edoxaban. Edoxaban (DU-176) is a selective, potent and orally active factor Xa (FXa) inhibitor with Kis of 0.561 nM and 2.98 nM for free FXa and prothrombinase, respectively. Edoxaban is an anticoagulant agent and can be used for stroke prevention. Edoxaban is also a weak inhibitor of thrombin and factor IXaβ (FIXa), with Kis of 6.00 μM and 41.7 μM, respectively, exhibits >10000-fold selectivity for FXa. Edoxaban has antithrombotic properties and has potential for thromboembolic diseases treatment.
    Edoxaban-d<sub>6</sub>
  • HY-156613
    Frunexian
    		Inhibitor
    Frunexian (EP-7041) is a selective and potent inhibitor of coagulation factor XI/activated factor XI, targeting to factor XIa. Frunexian exhibits antithrombotic activity, with no bleeding liability in rat mesenteric arterial puncture model. Frunexian can be used in extracorporeal membrane oxygenation (ECMO) research.
    Frunexian
  • HY-P990060
    Denecimig
    		Inhibitor
    Denecimig (Mim8) is a novel activated coagulation factor VIII-mimetic human bispecific antibody with anti-FIXa and anti-FX arms that potently stimulates FX activation resulting in efficacious haemostasis in vitro and in vivo.
    Denecimig
  • HY-10268B
    Betrixaban hydrochloride
    		Inhibitor
    Betrixaban (PRT054021) hydrochloride is a highly potent, selective, and orally efficacious factor Xa (fXa) inhibitor with an IC50 of 1.5 nM. Betrixaban hydrochloride shows antithrombotic effect.
    Betrixaban hydrochloride
  • HY-128889
    FXIa-IN-1
    		Inhibitor
    FXIa-IN-1 (compound EP-7041) is a potent β-lactam covalent heparin-derived factor XIa (fXIa) inhibitor.
    FXIa-IN-1
  • HY-10264C
    Edoxaban hydrochloride
    		Inhibitor
    Edoxaban (DU-176b) hydrochloride is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with Ki values of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban hydrochloride exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban hydrochloride can be used for preventing thromboembolic disease research.
    Edoxaban hydrochloride
  • HY-10268A
    Betrixaban maleate
    		Inhibitor
    Betrixaban (PRT054021) maleate is a highly potent, selective, and orally efficacious factor Xa (fXa) inhibitor with an IC50 of 1.5 nM. Betrixaban maleate shows antithrombotic effect.
    Betrixaban maleate